TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07224321: INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

Sponsor: Mannkind Corporation · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 100 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,460,800

Rescue Site Savings

+$962,800

Unlock Full NCT07224321 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07224321 Rescue Dossier →